ImmunoGen Balance Sheet Health
Financial Health criteria checks 4/6
ImmunoGen has a total shareholder equity of $561.6M and total debt of $72.1M, which brings its debt-to-equity ratio to 12.8%. Its total assets and total liabilities are $822.1M and $260.5M respectively.
Key information
12.8%
Debt to equity ratio
US$72.11m
Debt
| Interest coverage ratio | n/a |
| Cash | US$605.54m |
| Equity | US$561.60m |
| Total liabilities | US$260.51m |
| Total assets | US$822.10m |
Recent financial health updates
Recent updates
Financial Position Analysis
Short Term Liabilities: IMGN *'s short term assets ($766.9M) exceed its short term liabilities ($134.7M).
Long Term Liabilities: IMGN *'s short term assets ($766.9M) exceed its long term liabilities ($125.8M).
Debt to Equity History and Analysis
Debt Level: IMGN * has more cash than its total debt.
Reducing Debt: IMGN *'s debt to equity ratio has increased from 4.4% to 12.8% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: IMGN * has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if IMGN * has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.